ASCO 2026: Latest in prostate cancer

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

GLP-1 therapy associated with reduced breast cancer risk

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

GLP-1 use linked to improved survival in patients with cancer

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Aspirin use linked to improved survival in endometrial cancer

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC